Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Leap Therapeutics Inc (LPTX)

Leap Therapeutics Inc (LPTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,916
  • Shares Outstanding, K 41,440
  • Annual Sales, $ 0 K
  • Annual Income, $ -67,560 K
  • EBIT $ -67 M
  • EBITDA $ -67 M
  • 60-Month Beta -0.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.97
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.58
  • Most Recent Earnings $-0.40 on 08/14/25
  • Next Earnings Date 11/12/25 [--]
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 290.38% ( -17.93%)
  • Historical Volatility 214.64%
  • IV Percentile 41%
  • IV Rank 18.71%
  • IV High 1,152.85% on 07/09/25
  • IV Low 91.92% on 06/17/25
  • Put/Call Vol Ratio 0.00
  • Today's Volume 46
  • Volume Avg (30-Day) 387
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 9,879
  • Open Int (30-Day) 10,916

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate -0.24
  • Number of Estimates 1
  • High Estimate -0.24
  • Low Estimate -0.24
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +45.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3930 +7.71%
on 11/06/25
0.7770 -45.52%
on 10/09/25
-0.2031 (-32.42%)
since 10/07/25
3-Month
0.2323 +82.22%
on 08/14/25
0.9838 -56.97%
on 10/06/25
+0.1075 (+34.04%)
since 08/07/25
52-Week
0.2223 +90.42%
on 04/04/25
3.6097 -88.27%
on 11/13/24
-3.0467 (-87.80%)
since 11/07/24

Most Recent Stories

More News
Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025

Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population

LPTX : 0.4424 (+8.38%)
Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

CAMBRIDGE, Mass. , Oct. 9, 2025 /PRNewswire/ -- Leap Therapeutics (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has...

LPTX : 0.4424 (+8.38%)
Leap Therapeutics Announces $58.88M Private Placement

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Leap Therapeutics...

LPTX : 0.4424 (+8.38%)
Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

CAMBRIDGE, Mass. , Oct. 6, 2025 /PRNewswire/ -- Leap Therapeutics (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced $58,888,888...

LPTX : 0.4424 (+8.38%)
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion

EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:LPTX),(NASDAQ:IOBT),(NASDAQ:CELC),(NYSE:MAIA) EQNX::TICKER_END

CELC : 73.33 (-1.17%)
GTBP : 0.5922 (+6.99%)
IOBT : 0.8883 (+5.37%)
LPTX : 0.4424 (+8.38%)
MAIA : 1.1000 (unch)
Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025

CAMBRIDGE, Mass. , Sept. 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...

LPTX : 0.4424 (+8.38%)
Leap Therapeutics Reports Second Quarter 2025 Financial Results

CAMBRIDGE, Mass. , Aug. 14, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

LPTX : 0.4424 (+8.38%)
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe

KURA : 9.68 (-4.72%)
SHPH : 2.30 (-9.80%)
LPTX : 0.4424 (+8.38%)
NXTC : 8.90 (-9.37%)
ACET : 0.6390 (-5.59%)
Leap Therapeutics Stock Plunges To Record Low After Ending Gastric Cancer Drug Trials, Retail Bets On CRC Pipeline

While sirexatamab combined with tislelizumab and chemotherapy showed some activity in biomarker-specific populations, the study failed to generate a clear positive signal on progression-free survival endpoints....

PINK : 32.70 (-0.09%)
IWC : 146.52 (-1.27%)
VXF : 205.28 (-0.34%)
LPTX : 0.4424 (+8.38%)
Leap Therapeutics Reports Second Quarter 2023 Financial Results

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

LPTX : 0.4424 (+8.38%)

Business Summary

Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States.

See More

Key Turning Points

3rd Resistance Point 0.4440
2nd Resistance Point 0.4307
1st Resistance Point 0.4195
Last Price 0.4424
1st Support Level 0.3950
2nd Support Level 0.3817
3rd Support Level 0.3705

See More

52-Week High 3.6097
Fibonacci 61.8% 2.3157
Fibonacci 50% 1.9160
Fibonacci 38.2% 1.5163
Last Price 0.4424
52-Week Low 0.2223

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar